Tompkins Financial Corp Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY)

Tompkins Financial Corp lowered its position in Bristol-Myers Squibb (NYSE:BMY) by 3.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 11,648 shares of the biopharmaceutical company’s stock after selling 450 shares during the quarter. Tompkins Financial Corp’s holdings in Bristol-Myers Squibb were worth $745,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Lantz Financial LLC grew its stake in Bristol-Myers Squibb by 6.3% in the 2nd quarter. Lantz Financial LLC now owns 5,951 shares of the biopharmaceutical company’s stock valued at $381,000 after buying an additional 352 shares in the last quarter. Sciencast Management LP raised its stake in shares of Bristol-Myers Squibb by 214.0% during the 2nd quarter. Sciencast Management LP now owns 18,043 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 12,296 shares during the period. Cardinal Capital Management purchased a new position in Bristol-Myers Squibb during the 2nd quarter valued at about $2,206,000. FSM Wealth Advisors LLC grew its stake in Bristol-Myers Squibb by 22.1% during the second quarter. FSM Wealth Advisors LLC now owns 6,592 shares of the biopharmaceutical company’s stock valued at $414,000 after acquiring an additional 1,195 shares in the last quarter. Finally, Ignite Planners LLC grew its position in shares of Bristol-Myers Squibb by 2.3% during the 2nd quarter. Ignite Planners LLC now owns 7,866 shares of the biopharmaceutical company’s stock valued at $493,000 after purchasing an additional 180 shares in the last quarter. 74.98% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the transaction, the executive vice president now owns 27,868 shares in the company, valued at $1,706,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Robert M. Plenge sold 732 shares of the stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total value of $44,754.48. Following the completion of the transaction, the executive vice president now directly owns 6,584 shares in the company, valued at approximately $402,545.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the sale, the executive vice president now directly owns 27,868 shares in the company, valued at approximately $1,706,915. The disclosure for this sale can be found here. Company insiders own 0.08% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.1 %

BMY traded down $0.03 on Tuesday, hitting $58.55. 1,674,885 shares of the company were exchanged, compared to its average volume of 8,960,012. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.28 and a current ratio of 1.39. The firm has a fifty day simple moving average of $61.62 and a two-hundred day simple moving average of $65.11. The stock has a market capitalization of $122.32 billion, a PE ratio of 15.58, a price-to-earnings-growth ratio of 1.57 and a beta of 0.42. Bristol-Myers Squibb has a 12 month low of $58.33 and a 12 month high of $81.43.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). The firm had revenue of $11.23 billion for the quarter, compared to analysts’ expectations of $11.81 billion. Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. The business’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.93 earnings per share. Sell-side analysts expect that Bristol-Myers Squibb will post 7.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Daiwa Capital Markets initiated coverage on Bristol-Myers Squibb in a research note on Wednesday, June 28th. They set an “outperform” rating and a $70.00 price objective for the company. Credit Suisse Group cut their price objective on Bristol-Myers Squibb from $72.00 to $66.00 in a report on Wednesday, July 12th. Atlantic Securities lowered their target price on shares of Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, July 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of Bristol-Myers Squibb in a research note on Friday. Finally, Morgan Stanley reissued an “underweight” rating and issued a $59.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $70.67.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.